We found EN-RAGE as a novel inflammatory marker for pre-diabetes and for CHD [82, 83], IL17 for incident T2D and IL13 for pre-diabetes, incident T2D and insulin therapy [83]. Here, INS is linked to type 2 diabetes mellitus.